QuiaPEG Pharmaceuticals Holding AB (ST:QUIA) — Market Cap & Net Worth

$141.00K USD  · Skr1.31 Million SEK  · Rank #30893

Market Cap & Net Worth: QuiaPEG Pharmaceuticals Holding AB (QUIA)

QuiaPEG Pharmaceuticals Holding AB (ST:QUIA) has a market capitalization of $141.00K (Skr1.31 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30893 globally and #736 in its home market, demonstrating a -44.44% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying QuiaPEG Pharmaceuticals Holding AB's stock price Skr0.00 by its total outstanding shares 2620377659 (2.62 Billion). Analyse cash flow conversion of QuiaPEG Pharmaceuticals Holding AB to see how efficiently the company converts income to cash.

QuiaPEG Pharmaceuticals Holding AB Market Cap History: 2015 to 2025

QuiaPEG Pharmaceuticals Holding AB's market capitalization history from 2015 to 2025. Data shows change from $84.03 Billion to $141.00K (-71.82% CAGR).

Index Memberships

QuiaPEG Pharmaceuticals Holding AB is a constituent of 1 market index:

Index Total Market Cap Weight (%) Rank by Market Cap
First North Sweden PI
FNSESEKPI
$14.99 Billion 0.00% #258 of 281

Weight: QuiaPEG Pharmaceuticals Holding AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

QuiaPEG Pharmaceuticals Holding AB Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how QuiaPEG Pharmaceuticals Holding AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

6.44x

QuiaPEG Pharmaceuticals Holding AB's market cap is 6.44 times its annual revenue

Industry average: 3784.39x Lower than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2015 $84.03 Billion $14.40 Million $578.00K 5835.44x 145381.23x
2016 $91.42 Billion $916.00K $9.60 Million 99805.39x 9528.06x
2017 $20.11 Billion $3.93 Million -$4.47 Million 5114.13x N/A
2018 $45.12 Billion $3.38 Million -$12.05 Million 13361.59x N/A
2019 $45.98 Billion $4.47 Million -$21.11 Million 10295.65x N/A
2020 $21.88 Billion $1.86 Million -$27.71 Million 11754.72x N/A
2021 $7.52 Billion $216.00K -$22.43 Million 34833.63x N/A
2022 $1.81 Billion $5.57 Million -$24.38 Million 324.96x N/A
2023 $18.64 Million $4.37 Million -$16.52 Million 4.26x N/A
2024 $2.96 Million $460.00K -$28.93 Million 6.44x N/A

Competitor Companies of QUIA by Market Capitalization

Companies near QuiaPEG Pharmaceuticals Holding AB in the global market cap rankings as of May 4, 2026.

Key companies related to QuiaPEG Pharmaceuticals Holding AB by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
  • UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
  • argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#223 Vertex Pharmaceuticals Inc NASDAQ:VRTX $107.56 Billion $423.92
#367 Regeneron Pharmaceuticals Inc NASDAQ:REGN $72.88 Billion $701.42
#517 UCB SA BR:UCB $51.45 Billion €231.20
#568 argenx NV ADR NASDAQ:ARGX $45.97 Billion $787.95

QuiaPEG Pharmaceuticals Holding AB Historical Marketcap From 2015 to 2025

Between 2015 and today, QuiaPEG Pharmaceuticals Holding AB's market cap moved from $84.03 Billion to $ 141.00K, with a yearly change of -71.82%.

Year Market Cap Change (%)
2025 Skr141.00K -95.24%
2024 Skr2.96 Million -84.11%
2023 Skr18.64 Million -98.97%
2022 Skr1.81 Billion -75.93%
2021 Skr7.52 Billion -65.61%
2020 Skr21.88 Billion -52.42%
2019 Skr45.98 Billion +1.90%
2018 Skr45.12 Billion +124.39%
2017 Skr20.11 Billion -78.00%
2016 Skr91.42 Billion +8.80%
2015 Skr84.03 Billion --

End of Day Market Cap According to Different Sources

On May 3rd, 2026 the market cap of QuiaPEG Pharmaceuticals Holding AB was reported to be:

Source Market Cap
Yahoo Finance $141.00K USD
MoneyControl $141.00K USD
MarketWatch $141.00K USD
marketcap.company $141.00K USD
Reuters $141.00K USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About QuiaPEG Pharmaceuticals Holding AB

ST:QUIA Sweden Biotechnology
Market Cap
$141.00K
Skr1.31 Million SEK
Market Cap Rank
#30893 Global
#736 in Sweden
Share Price
Skr0.00
Change (1 day)
-16.67%
52-Week Range
Skr0.00 - Skr0.01
All Time High
Skr464.25
About

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more